ArticleMethods in molecular biology (Clifton, N.J.)2016
Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant.
Article in Methods in molecular biology (Clifton, N.J.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Post-Hoc Analysis of Potential Correlates of Protection of a Recombinant SARS-CoV-2 Spike Protein Extracellular Domain Vaccine Formulated with Advax-CpG55.2-Adjuvant.International journal of molecular sciences · 2024Trial
- Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine.Human vaccines & immunotherapeutics · 2024Review
- Prime-Pull Immunization of Mice with a BcfA-Adjuvanted Vaccine Elicits Sustained Mucosal Immunity That Prevents SARS-CoV-2 Infection and Pathology.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Review on Approved and Inprogress COVID-19 Vaccines.Iranian journal of pharmaceutical research : IJPR · 2022Review
- A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2022Review
- Review
- Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform.Nano research · 2022Review
- An evidence of microalgal peptides to target spike protein of COVID-19: In silico approach.Microbial pathogenesis · 2021Article
- Nanotherapeutics for treating coronavirus diseases.Journal of drug delivery science and technology · 2021Review
- Article
- Immunobiology and immunotherapy of COVID-19: A clinically updated overview.Journal of cellular physiology · 2021Review
- A domain-based vaccine construct against SARS-CoV-2, the causative agent of COVID-19 pandemic: development of self-amplifying mRNA and peptide vaccines.BioImpacts : BI · 2021Article
- Physicochemical properties of SARS-CoV-2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control.Electrophoresis · 2020Review
- Adjuvants for Coronavirus Vaccines.Frontiers in immunology · 2020Review
- Coronaviruses: An Updated Overview of Their Replication and Pathogenesis.Methods in molecular biology (Clifton, N.J.) · 2020Review
- The Safety of an Adjuvanted Autologous Cancer Vaccine Platform in Canine Cancer Patients.Veterinary sciences · 2018Article
- Development of Middle East Respiratory Syndrome Coronavirus vaccines - advances and challenges.Human vaccines & immunotherapeutics · 2018Review
- Advax4 delta inulin combination adjuvant together with ECMX, a fusion construct of four protective mTB antigens, induces a potent Th1 immune response and protects mice against Mycobacterium tuberculosis infection.Human vaccines & immunotherapeutics · 2017Article
- Delta inulin-based adjuvants promote the generation of polyfunctional CD4Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given periodic outbreaks of fatal human infections caused by coronaviruses, development of an optimal coronavirus vaccine platform capable of rapid production is an ongoing priority. This chapter describes the use of an insect cell expression system for rapid production of a recombinant vaccine against severe acute respiratory syndrome coronavirus (SARS). Detailed methods are presented for expression, purification, and release testing of SARS recombinant spike protein antigen, followed by adjuvant formulation and animal testing. The methods herein described for rapid development of a highly protective SARS vaccine are equally suited to rapid development of vaccines against other fatal human coronavirus infections, e.g., the MERS coronavirus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.